Phaseline

Targets › TNNT2

TNNT2 (Troponin T, cardiac muscle): drug programs, companies and trials

1 program from 1 company in 4 trials: 3 Phase 3, 1 Phase 4; Cardiovascular, Other; next expected readout Jun 2028.

Troponin T is the tropomyosin-binding subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity. (UniProt, P45379)

Open in Phaseline: the race on TNNT2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tenax TherapeuticsLevosimendan (TNX-103)
Phosphodiesterase 3 inhibitor; Troponin, cardiac muscle positive modulator
PDE3A, PDE3B, TNNC1, TNNI3, TNNT2Phase 3Pulmonary Hypertension Associated With HFpEF; Pulmonary Hypertension; Mechanical Ventilation; Cardiogenic ShockJun 2028

Conditions

Pulmonary Hypertension Associated With HFpEF (1) Pulmonary Hypertension (1) Mechanical Ventilation (1) Cardiogenic Shock (1)

Modalities

small molecule (1)

Companies

Tenax Therapeutics (1)

Related targets

PDE3A (1) PDE3B (1) TNNC1 (1) TNNI3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.